Eton Pharmaceuticals, Inc. Q4 FY2024 earnings call

• Corporate vision is to build a large leading ultra-rare disease company by putting patients first. They have a three-pillar strategy: organic growth of existing products, development of internal pipeline, and external acquisitions.
• Sixteen straight quarters of product revenue growth for Alcindi Sprinkle. Acquisitions of Acrolex and Galzum will impact 2025 revenue.
• IncraLex acquisition: targets pediatric patients with severe primary insulin-like growth factor one deficiency, has potential for growth through increased adoption, price adjustment, and label harmonization.
• Adrenal insufficiency franchise: Alcindi Sprinkle is a proprietary hydrocortisone formulation, and ET400 is in development for an oral liquid formulation to address unmet needs.
• Wilson Disease and Galzum: Galzum is the only FDA-approved zinc therapy for Wilson Disease, with opportunities to improve access, affordability, and awareness. ET700 is a next-generation product in development.
• Pipeline updates: ET600 passed a pivotal clinical study and is near NDA submission for treating diabetes insipidus; Amglidia is under development for neonatal diabetes; ZENIO is a needle-free auto-injector for adrenal crisis.

In the fourth quarter, Eton Pharmaceuticals reported revenue of $11.6 million, a year-over-year increase of 59%. All revenue came from product sales. The robust growth was driven by Alcindi Sprinkle and cargumic acid. The IncraLex acquisition contributed less than $200,000 to Q4 revenue, and Galzum's acquisition had no material impact. Cargumic acid and Alcindi Sprinkle are key products, with Alcindi having sixteen straight quarters of product revenue growth. The revenue contribution of each segment isn't explicitly broken down by percentage, but key products like Alcindi, cargumic acid, IncraLex, and Galzum are mentioned with their growth dynamics.

• Adjusted gross margins are expected to improve in 2025, with higher-margin products like IncraLex, Galzum, and ET400 driving growth. Anticipate adjusted gross margins to reach ~70% in 2025 and ~75% by 2028.
• Revenue guidance for 2025: exit at an approximately $80 million annual revenue run rate, driven by US IncraLex revenue contributing in Q2, Galzum relaunch contributing in Q3, and ET400 contributing in the second half of the year.
• Long-term goal is to reach $100 million in revenue in the near term and higher levels as the pipeline comes to market.

• Label harmonization for IncraLex faces uncertainties, though there is optimism based on real-world data.
• Market penetration risks for new products like IncraLex, Galzum, and ET600, as the target patient populations are small and underdiagnosed.
• Manufacturing delays for ZENIO, related to equipment challenges, which could impact timelines for the needle-free auto-injector.

Q: On IncraLex, how quickly can they get back to 185 patients?

A: Sean Brynjelsen is optimistic, noting the product launch has gone well with 14 new patients added in a few months and no signs of slowing.

Q: On label expansion opportunity for IncraLex, what's the penetration in Europe and potential here?

A: David Krempa states there are significantly more patients in Europe but similar issues of underdiagnosis and undertreatment, and they expect similar penetration efforts there.

Q: On ET600, thoughts on penetration and pricing?

A: Sean Brynjelsen mentions pricing will be higher than Alcindi Sprinkle due to fewer patients, and penetration is expected to be significant with pent-up demand.

Q: On SG&A expenses in 2025?

A: James Gruber expects SG&A to increase by 30-40% in 2025 due to investments in new sales teams and product launches, then moderate to low double-digit growth beyond 2025.

Q: Gating factors for IncraLex label unification?

A: David Krempa says aggregating data from the European registry and having a meeting with the FDA to discuss strong data supporting label harmonization is key.

Q: ET400 launch expectations?

A: Ipek Erwan notes there will be a slower ramp initially post-approval but expects accelerated growth in the first half of 2026 as patients switch during regular checkups.